In Section C, participants will obtain ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment till condition progression or perhaps the individuals are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit products and solutions within 3 days https://abbv-744inacutemyeloidleu13467.win-blog.com/12427347/the-2-minute-rule-for-is-abbv-744-effective-for-hematologic-cancers